562 related articles for article (PubMed ID: 15917162)
1. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination?
Wildemeersch D; Janssens D; Weyers S
Maturitas; 2005 Jun; 51(2):207-14. PubMed ID: 15917162
[TBL] [Abstract][Full Text] [Related]
2. Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women.
Wildemeersch D; Janssens D; Schacht E; Pylyser K; de Wever N
Gynecol Endocrinol; 2005 Jun; 20(6):336-42. PubMed ID: 16019384
[TBL] [Abstract][Full Text] [Related]
3. Endometrial suppression with a new 'frameless' levonorgestrel releasing intrauterine system in perimenopausal and postmenopausal women: a pilot study.
Wildemeersch D; Schacht E
Maturitas; 2000 Jul; 36(1):63-8. PubMed ID: 10989243
[TBL] [Abstract][Full Text] [Related]
4. Endometrial safety with a low-dose intrauterine levonorgestrel-releasing system after 3 years of estrogen substitution therapy.
Wildemeersch D; Schacht E; Wildemeersch P; Calleweart K; Pylyser K; De Wever N
Maturitas; 2004 May; 48(1):65-70. PubMed ID: 15223110
[TBL] [Abstract][Full Text] [Related]
5. Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution.
Wildemeersch D; Pylyser K; De Wever N; Pauwels P; Tjalma W
Maturitas; 2007 Jun; 57(2):205-9. PubMed ID: 17227699
[TBL] [Abstract][Full Text] [Related]
6. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
Wildemeersch D; Janssens D; Andrade A
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
[TBL] [Abstract][Full Text] [Related]
7. Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems.
Wildemeersch D; Janssens D; Vrijens M; Weyers S
Contraception; 2005 Jun; 71(6):465-9. PubMed ID: 15914138
[TBL] [Abstract][Full Text] [Related]
8. Safety and comfort of long-term continuous combined transdermal estrogen and intrauterine levonorgestrel administration for postmenopausal hormone substitution - a review.
Wildemeersch D
Gynecol Endocrinol; 2016 Aug; 32(8):598-601. PubMed ID: 27117308
[TBL] [Abstract][Full Text] [Related]
9. Why perimenopausal women should consider to use a levonorgestrel intrauterine system.
Wildemeersch D
Gynecol Endocrinol; 2016 Aug; 32(8):659-661. PubMed ID: 26930021
[TBL] [Abstract][Full Text] [Related]
10. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy.
Varila E; Wahlström T; Rauramo I
Fertil Steril; 2001 Nov; 76(5):969-73. PubMed ID: 11704119
[TBL] [Abstract][Full Text] [Related]
11. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
[TBL] [Abstract][Full Text] [Related]
12. Potential health benefits of continuous LNG-IUS combined with parenteral ERT for seamless menopausal transition and beyond--a commentary based on clinical experience.
Wildemeersch D
Gynecol Endocrinol; 2013 Jun; 29(6):569-73. PubMed ID: 23465041
[TBL] [Abstract][Full Text] [Related]
13. Treatment of primary and secondary dysmenorrhea with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
Wildemeersch D; Schacht E; Wildemeersch P
Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):192-8. PubMed ID: 11848648
[TBL] [Abstract][Full Text] [Related]
14. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
[TBL] [Abstract][Full Text] [Related]
15. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
Wildemeersch D; Schacht E
Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
[TBL] [Abstract][Full Text] [Related]
16. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
Lethaby A; Hussain M; Rishworth JR; Rees MC
Cochrane Database Syst Rev; 2015 Apr; (4):CD002126. PubMed ID: 25924648
[TBL] [Abstract][Full Text] [Related]
17. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
Lethaby AE; Cooke I; Rees M
Cochrane Database Syst Rev; 2005 Oct; (4):CD002126. PubMed ID: 16235297
[TBL] [Abstract][Full Text] [Related]
18. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up.
Wildemeersch D; Janssens D; Pylyser K; De Wever N; Verbeeck G; Dhont M; Tjalma W
Maturitas; 2007 Jun; 57(2):210-3. PubMed ID: 17270370
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
[TBL] [Abstract][Full Text] [Related]
20. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system.
Hidalgo MM; Hidalgo-Regina C; Bahamondes MV; Monteiro I; Petta CA; Bahamondes L
Contraception; 2009 Jul; 80(1):84-9. PubMed ID: 19501221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
